Press coverage about Simulations Plus (NASDAQ:SLP) has trended somewhat positive this week, according to Accern Sentiment. The research firm identifies negative and positive news coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Simulations Plus earned a news sentiment score of 0.09 on Accern’s scale. Accern also gave news articles about the technology company an impact score of 45.2940339967051 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
Simulations Plus opened at $20.05 on Thursday, according to MarketBeat. The stock has a market capitalization of $342.19 million, a P/E ratio of 58.97 and a beta of -0.54. Simulations Plus has a twelve month low of $11.50 and a twelve month high of $20.10.
Simulations Plus (NASDAQ:SLP) last posted its earnings results on Monday, April 9th. The technology company reported $0.11 earnings per share for the quarter, meeting the Zacks’ consensus estimate of $0.11. The business had revenue of $7.36 million for the quarter, compared to analysts’ expectations of $7.37 million. Simulations Plus had a net margin of 30.65% and a return on equity of 26.19%. equities analysts expect that Simulations Plus will post 0.4 EPS for the current year.
A number of research firms recently weighed in on SLP. BidaskClub raised shares of Simulations Plus from a “hold” rating to a “buy” rating in a research note on Monday, May 7th. ValuEngine raised shares of Simulations Plus from a “buy” rating to a “strong-buy” rating in a research note on Monday, May 14th. Finally, Zacks Investment Research raised shares of Simulations Plus from a “hold” rating to a “buy” rating and set a $18.00 target price on the stock in a research note on Thursday, March 22nd.
In other Simulations Plus news, Chairman Walter S. Woltosz sold 18,500 shares of the company’s stock in a transaction dated Tuesday, May 29th. The shares were sold at an average price of $19.27, for a total transaction of $356,495.00. Following the sale, the chairman now directly owns 5,454,408 shares of the company’s stock, valued at $105,106,442.16. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CFO John Robert Kneisel sold 2,991 shares of the company’s stock in a transaction dated Friday, April 20th. The stock was sold at an average price of $17.64, for a total transaction of $52,761.24. The disclosure for this sale can be found here. In the last three months, insiders sold 58,491 shares of company stock worth $996,446. 33.45% of the stock is currently owned by insiders.
About Simulations Plus
Simulations Plus, Inc develops drug discovery and development software for mechanistic modeling and simulation worldwide. The company offers GastroPlus, which simulates the absorption, pharmacokinetics (PK), and pharmacodynamics of drugs administered to humans and animals; DDDPlus that simulates in vitro laboratory experiments, which measure the rate of dissolution of the drug and additives in a dosage form; and MembranePlus, which simulates laboratory experiments.
Receive News & Ratings for Simulations Plus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Simulations Plus and related companies with MarketBeat.com's FREE daily email newsletter.